13 · Where this brief could be wrong

Where this brief could be wrong

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Where this brief could be wrong across your briefs

Our biggest conclusion, the strongest case against it, and what would settle it.

RED TEAM

Base case. Pan-RAS drugs are moving toward first-line pancreatic cancer, on single-arm data. Analysis

Counter-case. Response rates in small, selected groups often shrink in randomized trials, and adding a drug that also blocks normal RAS to chemotherapy may cost tolerability that a short single-arm study does not show.

What would settle it. RASolute 303’s survival comparison against chemotherapy alone, and full safety tables for both drugs.

ConsensusCounter-caseWhat would settle it
Xanamem may still work in older patientsThe subgroup came after a missed primary, and its mean slowing was not significantA new trial in older patients with that as its primary
Sanofi may bid for InsmedThe report cites unnamed sources and no price; companies weigh many deals they never makeAn announcement by either company

BLIND SPOT CHECK

GlobeNewswire’s search and the Business Wire newsroom did not load, so wire coverage was partial. We read Revolution’s release through Investing News, Alnylam’s through Yahoo Finance and Actinogen’s through BioSpace, and read DISCO’s release through Yahoo Finance. The Insmed report is secondhand, the CME FedWatch reading comes through a newsletter, and the Insmed report has no public primary copy. ClinicalTrials.gov, Open Targets, ChEMBL and PubMed were reached through their connectors. Early European and Asian releases may be missing.